Skip to main content
. Author manuscript; available in PMC: 2012 Dec 1.
Published in final edited form as: Anesthesiology. 2011 Dec;115(6):1316–1327. doi: 10.1097/ALN.0b013e3182315eb2

Figure 3.

Figure 3

Pharmacogenetics of the β-blocker bucindolol in chronic heart failure. Shown are Kaplan-Meyer curves showing survival stratified by treatment group and the β1Arg- or β1Gly389 polymorphism. Those with the β1Arg389 genotype receiving bucindolol had a 38% improvement in survival over placebo patients of the same genotype. Gly389 carriers on bucindolol showed no improvement. From Liggett SB et al., Proc Natl Acad Sci USA 2006; 103:11288-93. Reprinted with permission from the National Academy of Sciences, USA.63